Transition Therapeutics, Inc. (TTHI) is no longer a publicly traded company. The company was a biopharmaceutical company that focused on the development of novel therapeutics for the treatment of age-related diseases and conditions such as Alzheimer's disease, diabetes, and osteoarthritis.
In 2016, Transition Therapeutics, Inc. was acquired by OPKO Health, Inc., a healthcare company that specializes in the development and commercialization of novel products for diagnostics and therapeutics. As a result of the acquisition, Transition Therapeutics, Inc. became a wholly-owned subsidiary of OPKO Health, Inc.
Transition Therapeutics, Inc. (TTHI) is no longer a publicly traded company. The company was a biopharmaceutical company that focused on the development of novel therapeutics for the treatment of age-related diseases and conditions such as Alzheimer's disease, diabetes, and osteoarthritis.